Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
18
Not yet recruiting, industry sponsors, Ophthalmology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed464
18 trials
Showing 1 to 18, recently updated first.
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07951515 · 1,188 participants (planned) · Start Dec 21, 2026 · Primary completion Nov 19, 2029
Drug: MK-8748; Aflibercept · For: Retinal Vein Occlusion; Macular Edema
- IIIb Trial for RC28-E Injection in Participants With DME and wAMDPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07936487 · 350 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 1, 2028
Drug: RC28-E · For: Diabetic Macular Edema (DME); wAMD
Sites: Beijing, China
- A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)Pivotal-lookingNot yet recruiting
Mighty Therapeutics Inc.Industry
NCT07927010 · 300 participants (planned) · Start Nov 2026 · Primary completion Mar 2029
Drug: 1 % Bevemipretide; 2% Bevemipretide · For: Dry AMD; Age-Related Macular Degeneration (AMD)
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07841899 · 450 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Diabetic Macular Edema (DME)
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07842016 · 450 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Diabetic Macular Edema (DME)
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07816315 · 500 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Wet Age Related Macular Degeneration
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07816289 · 400 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Ranibizumab · For: Wet Age-related Macular Degeneration
- An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Pivotal-lookingNot yet recruiting
Annexon, Inc.Industry
NCT07807969 · 605 participants (planned) · Start Sep 30, 2026 · Primary completion Jul 31, 2029
Drug: Vonaprument · For: Geographic Atrophy
Sites: Sarasota, Florida; St. Petersburg, Florida; Hagerstown, Maryland · 7 sites in all
- Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersPivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07791199 · 2,300 participants (planned) · Start Dec 31, 2026 · Primary completion Oct 31, 2030
Drug: Deucravacitinib · For: Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis and 1 more
- 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher SyndromePivotal-lookingNot yet recruiting
Nacuity Pharmaceuticals, Inc.Industry
NCT07290530 · 80 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: N-acetylcysteine amide · For: Retinitis Pigmentosa (RP); Usher Syndrome
- Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry EyePivotal-lookingNot yet recruiting
Cambium Bio LimitedIndustry
NCT06903611 · 475 participants (planned) · Start Oct 1, 2026 · Primary completion Nov 30, 2027
Drug: CAM-101 · For: Dry Eye Disease; Dry Eye; Dry Eyes Chronic and 1 more
- Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle GlaucomaPivotal-lookingNot yet recruiting
Ache Laboratorios Farmaceuticos S.A.Industry
NCT07617532 · 336 participants (planned) · Start Jun 2026 · Primary completion Mar 2028
Drug: Product DNN.31.19.026; COSOPT® · For: Ocular Hypertension; Primary Open Angle Glaucoma
- This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.Pivotal-lookingNot yet recruiting
Shenzhen Oculgen Biomedical Technology Co., Ltd.Industry
NCT07520318 · 255 participants (planned) · Start Apr 17, 2026 · Primary completion Feb 1, 2029
Drug: bispecific anti-VEGF and anti-complement · For: Adults With Neovascular Age-related Macular Degeneration
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07489586 · 356 participants (planned) · Start Mar 2026 · Primary completion Dec 2026
Drug: QL1207H injection; Aflibercept 8 mg · For: Neovascular Age-Related Macular Degeneration (nAMD)
- Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/IIPivotal-lookingNot yet recruiting
PT. Prodia Stem Cell IndonesiaIndustry
NCT05909488 · 30 participants (planned) · Start May 2026 · Primary completion Jul 2027
Drug: 1.5 x 10^6 UC-MSC + CM; 5 x 10^6 UC-MSC + CM · For: Retinitis Pigmentosa
Sites: Yogyakarta, Indonesia
- A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye PatientsPivotal-lookingNot yet recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06942793 · 396 participants (planned) · Start May 20, 2025 · Primary completion Oct 20, 2025
Drug: CsA-PG Ophthalmic Gel; CsA Ophthalmic Gel · For: Dry Eye Disease
- A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular DegenerationPivotal-lookingNot yet recruiting
Rophibio, Inc.Industry
NCT06470373 · 434 participants (planned) · Start Jul 2025 · Primary completion Sep 2026
Drug: RBS-001 Solution for intravitreal injection; Eylea® Solution for intravitreal injection · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Phoenix, Arizona; Springdale, Arkansas; Erie, Pennsylvania · 7 sites in all
- Adjunct Episcleral Brachytherapy for PCVPivotal-lookingNot yet recruiting
Salutaris Medical Devices, Inc.Industry
NCT05251636 · 159 participants (planned) · Start Mar 2025 · Primary completion Sep 2026
Drug: Aflibercept Injection · For: Age-Related Macular Degeneration; Polypoid Choroidal Vasculopathy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.